Basaglar Sales Level Off For Lilly
Second-Quarter Sales Stagnant, While First-Half Turnover Is Up By A Tenth
Executive Summary
Eli Lilly has seen sales of its Basaglar insulin glargine hybrid remain static in the second quarter of 2020. However, the company reported total sales for the first half that were up by a tenth compared to the first half of 2019.
You may also be interested in...
Will Eli Lilly’s Rezvoglar Be Able To Compete With Interchangeable Semglee?
The FDA has approved the second biosimilar insulin glargine rival to Lantus, in the form of Eli Lilly’s Rezvoglar. However, Viatris’ recently relaunched Semglee version has an interchangeability designation on its side.
Mylan And Biocon Launch Semglee Insulin Glargine In US
Mylan and Biocon have launched their Semglee version of insulin glargine in the US, revealing pricing details for the Lantus rival. At the same time, the firms have offered an update on their attempts to have Semglee classified as a biosimilar as they seek an interchangeability designation.
Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount
Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.